Aika

Aika Therapeutics is a San Diego-based biotechnology company focused on the discovery and development of next-generation precision oncology therapies. Founded by the leadership team behind Turning Point Therapeutics, the company utilizes a proprietary structure-based drug design platform to create potent and selective small molecule inhibitors. Aika's primary mission is to address the limitations of current cancer treatments, particularly the emergence of drug resistance in patients with oncogenic drivers. The company's pipeline targets validated but challenging kinase mutations in various solid tumors. Headquartered in San Diego, Aika aims to continue the legacy of innovation in the kinase inhibitor space established by its founders.